Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-20-032865
Filing Date
2020-12-07
Accepted
2020-12-07 16:15:13
Documents
1
Period of Report
2020-11-30

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2202
  Complete submission text file 0000899243-20-032865.txt   3547
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Issuer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ARRAY BIOPHARMA INC. 3200 WALNUT ST. BOULDER CO 80301
Business Address
Oltmans Curtis Gale (Reporting) CIK: 0001714982 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38978 | Film No.: 201372895